No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1614-1621

  Thiel, U ^a   Wawer, A ^a   Wolf, P ^b   Badoglio, M ^c   Santucci, A ^d   Klingebiel, T ^e   Basu, O ^e   Borkhardt, A ^f   Laws, H J ^f   Kodera, Y ^g,h   Yoshimi, A ^h   Peters, C ⁱ   Ladenstein, R ⁱ   Pession, A ^j   Prete, A ^a   Urban, E C ^k   Schwinger, W ^k   Bordigoni, P ^l   Salmon, A ^l   Diaz, M A ^m   Afanasyev, B ⁿ   Lisukov, I ⁿ   Morozova, E ⁿ   Toren, A ^o   Bielorai, B ^o   Korsakas, J ^p   Fagioli, F ^q   Caselli, D ^r   Ehninger, G ^s   Gruhn, B ^t   Dirksen, U ^u   Abdel Rahman, F ^v   Aglietta, M ^w   Mastrodicasa, E ^d   Torrent, M ^x   Corradini, P ^y   Demeocq, F ^z   Dini, G ^aa   Dreger, P ^ab   Eyrich, M ^ac   Gozdzik, J ^ad   Guilhot, F ^ae   Holler, E ^af   Koscielniak, E ^ag   Messina, C ^ah   Nachbaur, D ^ai   Sabbatini, R ^aj   Oldani, E ^ak   Ottinger, H ^al   Ozsahin, H ^am   Schots, R ^an   Siena, S ^ao   Stein, J ^ap   Sufliarska, S ^aq   Unal, A ^ar   Ussowicz, M ^as   Schneider, P ^at   Woessmann, W ^au   Jurgens H ^u   Bregni, M ^av   Burdach, S ^a   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY OF PERUGIA   (Italy)

^e GOETHE UNIVERSITY   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g AICHI MEDICAL UNIVERSITY   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ ST ANNA CHILDREN S HOSPITAL   (Austria)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l CHU NANCY BRABOIS   (France)

^m HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

ⁿ PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^o SHEBA MEDICAL CENTER   (Israel)

^p VILNIUS UNIVERSITY   (Lithuania)

^q REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^r UNIVERSITY OF FLORENCE   (Italy)

^s UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^t FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^u UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^v KING HUSSEIN CANCER CENTER   (Jordan)

^w Department of Istitutoperl a Ricercaela Curadel Cancro ^*  (Italy)

^x HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^y UNIVERSITY OF MILAN   (Italy)

^z UNIVERSITÉ CLERMONT AUVERGNE   (France)

^aa G GASLINI INSTITUTE   (Italy)

^ab UNIVERSITY OF HEIDELBERG   (Germany)

^ac UNIVERSITY OF WÜRZBURG   (Germany)

^ad JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^ae POITIERS UNIVERSITY HOSPITAL   (France)

^af UNIVERSITY OF REGENSBURG   (Germany)

^ag OLGAHOSPITAL   (Germany)

^ah UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^ai UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^aj UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^ak OSPEDALI RIUNITI   (Italy)

^al UNIVERSITY HOSPITAL ESSEN   (Germany)

^am Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^an UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^ao OSPEDALE NIGUARDA CA GRANDA   (Italy)

^ap SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^aq Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^ar Kapadokya BMT Center   (Turkey)

^as WROCLAW MEDICAL UNIVERSITY   (Poland)

^at HÔPITAL CHARLES NICOLLE   (France)

^au UNIVERSITY HOSPITAL GIESSEN   (Germany)

^av San Giuseppe Hospital   (Italy)

more..

Author keywords

Advanced stage ewing tumor; Allogeneic stem cell transplantation; Graft versus tumor effect; Haploidentical stem cell transplantation; Reduced high intensity conditioning chemotherapy

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN; MELPHALAN; OKT 3; THIOTEPA; THYMOCYTE ANTIBODY; TOPOTECAN; TREOSULFAN; VINCRISTINE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; ENGRAFTMENT; EWING SARCOMA; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH INTENSITY CONDITIONING; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME; WHOLE BODY RADIATION;

EID: 79952638943     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq703     Document Type: Article

References (31)

1. Staege MS, Hutter C, Neumann I et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. ancer Res 2004; 64: 8213-8221.
2. Schmidt D, Harms D, Burdach S. Malignant peripheral neuroectodermal tumours of childhood and adolescence. Virchows Arch A Pathol Anat Histopathol 1985; 406: 351-365.
3. Richter GH, Plehm S, Fasan A et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl cad Sci U S A 2009; 106: 5324-5329.
4. Burdach S, Plehm S, Unland R et al. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009; 8: 1991-1996.
5. Schmidt D, Herrmann C, Jurgens H, Harms D. Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric umor Registry. Cancer 1991; 68: 2251-2259.
6. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165.
7. Dockhorn-Dworniczak B, Schafer KL, Dantcheva R et al. [Molecular genetic detection of t(11;22)(q24;12) translocation in Ewing sarcoma and malignant peripheral euroectodermal tumors]. Pathologe 1994; 15: 103-112.
8. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study roup. J Clin Oncol 2000; 18: 3108-3114.
9. Paulussen M, Braun-Munzinger G, Burdach S et al. [Results of treatment of primary exclusively pulmonary metastatic Ewing sarcoma. A retrospective analysis of 41 patients]. Klin adiatr 1993; 205: 210-216.
10. Burdach S. Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplants. Pediatr Transplant 2004; 8 (Suppl 5): 67-82.
11. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative wing Sarcoma Studies. Ann Oncol 1998; 9: 275-281.
12. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, totalbody irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812-2820.
13. Burdach S, Thiel U, Schoniger M et al. Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. Bone Marrow Transplant 2010; 45: 483-489.
14. Burdach S, Meyer-Bahlburg A, Laws HJ et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21: 3072-3078.
15. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 000; 343: 750-758.
16. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
17. Bregni M, Bernardi M, Ciceri F, Peccatori J. Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 2004; 26: 95-108.
18. Burdach S, van Kaick B, Laws HJ et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000; 1: 1451-1462.
19. Lang P, Pfeiffer M, Muller I et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor ffects. Klin Padiatr 2006; 218: 321-326.
20. Koscielniak E, Gross-Wieltsch U, Treuner J et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with elapse of metastatic disease. J Clin Oncol 2005; 23: 242-244.
21. Lucas KG, Schwartz C, Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer 2008; 51: 142-144.
22. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381-387.
23. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388-1395.
24. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
25. Burdach S, Peters C, Paulussen M et al. Improved relapse free survival in patients with poor prognosis Ewing's sarcoma after consolidation with hyperfractionated total body irradiation and fractionated high dose melphalan followed by high dose etoposide and hematopoietic rescue. Bone Marrow Transplant 1991; 7 (Suppl 2): 95.
26. Frohlich B, Ahrens S, Burdach S et al. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS]. Klin Padiatr 1999; 211: 284-290.
27. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001; 19: 870-880.
28. Kyriakou C, Canals C, Finke J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951-3958.
29. Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann ncol 2002; 13: 157-160.
30. Haeusler J, Ranft A, Boelling T et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116: 443-450.
31. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-4393.